| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/AJG.2015.20 |
| P698 | PubMed publication ID | 25732417 |
| P2093 | author name string | Ken Sato | |
| Masanobu Yamada | |||
| Satoru Kakizaki | |||
| Yuichi Yamazaki | |||
| Hiroaki Hashizume | |||
| Motoyasu Kusano | |||
| Norio Horiguchi | |||
| Masatoshi Yanagisawa | |||
| Kenichi Hosonuma | |||
| P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
| The PPARs: from orphan receptors to drug discovery | Q28371618 | ||
| Fenofibrate in primary biliary cirrhosis: a pilot study. | Q33912957 | ||
| National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer | Q34255849 | ||
| New fibrate use and acute renal outcomes in elderly adults: a population-based study | Q34268619 | ||
| Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials | Q34550505 | ||
| Fenofibrate for patients with asymptomatic primary biliary cirrhosis | Q36502610 | ||
| Ursodeoxycholic acid: Mechanism of action and novel clinical applications | Q37012207 | ||
| Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis | Q37760788 | ||
| Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid | Q39293482 | ||
| The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities | Q42284522 | ||
| Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice | Q42526889 | ||
| Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid | Q43483632 | ||
| Application of the Mayo primary biliary cirrhosis survival model to Mayo liver transplant patients | Q43537719 | ||
| Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients | Q43903202 | ||
| Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients | Q44617739 | ||
| Effectiveness of fenofibrate in comparison to bezafibrate for patients with asymptomatic primary biliary cirrhosis. | Q45963523 | ||
| Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid | Q46126105 | ||
| Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis | Q46408092 | ||
| B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid | Q46484331 | ||
| The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study | Q46614923 | ||
| Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans | Q46637413 | ||
| Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis | Q46775425 | ||
| Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. | Q50790143 | ||
| Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. | Q54032405 | ||
| The results of a randomized double blind controlled trial evaluating malotilate in primary biliary cirrhosis. A European multicentre study group | Q70590270 | ||
| Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis | Q73223349 | ||
| CONSORT revised--improving the reporting of randomized trials | Q73770279 | ||
| TNFSF9 expression in primary biliary cirrhosis and its clinical significance | Q83372673 | ||
| Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy | Q83708477 | ||
| Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid | Q83735808 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| dyslipidemia | Q66291209 | ||
| P304 | page(s) | 423-431 | |
| P577 | publication date | 2015-03-03 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. | |
| P478 | volume | 110 |
| Q30244056 | Autoimmune liver diseases in the Asia-Pacific region: Proceedings of APASL symposium on AIH and PBC 2016. |
| Q91431676 | Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis |
| Q92326834 | Cholestatic liver diseases: An era of emerging therapies |
| Q57111104 | Cholestatic liver diseases: new targets, new therapies |
| Q62803350 | Combination Therapy of Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis: The End of the Steroid Era in Autoimmune Liver Diseases? |
| Q54040784 | Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q47201402 | Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. |
| Q93046523 | Effectiveness of bezafibrate and ursodeoxycholic acid in patients with primary biliary cholangitis: a meta-analysis of randomized controlled trials |
| Q47615113 | Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. |
| Q46135644 | From pathogenesis to novel therapies in the treatment of primary biliary cholangitis |
| Q38620686 | It is time to change primary biliary cirrhosis (PBC): New nomenclature from "cirrhosis" to "cholangitis", and upcoming treatment based on unveiling pathology |
| Q39584105 | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score |
| Q47223909 | New therapies target the toxic consequences of cholestatic liver disease |
| Q93141274 | Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis |
| Q38911238 | Obeticholic acid for the treatment of primary biliary cholangitis |
| Q38628470 | Obeticholic acid for the treatment of primary biliary cirrhosis |
| Q39216355 | Old and new treatments for primary biliary cholangitis |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q39047912 | Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics |
| Q57141930 | Primary biliary cirrhosis |
| Q38554677 | Primary biliary cirrhosis: safety and benefits of established and emerging therapies |
| Q37072380 | Proposed therapies in primary biliary cholangitis |
| Q28076353 | Recent advances in the diagnosis and treatment of primary biliary cholangitis |
| Q85540879 | Response to Licinio et al |
| Q37628845 | Self-Reported Snoring Is Associated with Dyslipidemia, High Total Cholesterol, and High Low-Density Lipoprotein Cholesterol in Obesity: A Cross-Sectional Study from a Rural Area of China |
| Q92157055 | Structural and functional characterization of a novel acidophilic 7α-hydroxysteroid dehydrogenase |
| Q26778511 | Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis |
| Q52624982 | The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. |
| Q90013058 | Therapeutic and immunological interventions in primary biliary cholangitis: from mouse models to humans |
Search more.